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Abstract
Background: Population-based testing for BRCA1/2 mutations detects the high proportion of carriers not identified by cancer family history 
(FH)–based testing. We compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi 
Jewish (AJ) women.
Methods: A decision-analytic model was developed to compare lifetime costs and effects amongst AJ women in the UK of BRCA founder-mutation 
testing amongst: 1) all women in the population age 30 years or older and 2) just those with a strong FH (≥10% mutation risk). The model assumes 
that BRCA carriers are offered risk-reducing salpingo-oophorectomy and annual MRI/mammography screening or risk-reducing mastectomy. Model 
probabilities utilize the Genetic Cancer Prediction through Population Screening trial/published literature to estimate total costs, effects in terms of 
quality-adjusted life-years (QALYs), cancer incidence, incremental cost-effectiveness ratio (ICER), and population impact. Costs are reported at 2010 
prices. Costs/outcomes were discounted at 3.5%. We used deterministic/probabilistic sensitivity analysis (PSA) to evaluate model uncertainty.
Results: Compared with FH-based testing, population-screening saved 0.090 more life-years and 0.101 more QALYs resulting in 33 days’ gain in 
life expectancy. Population screening was found to be cost saving with a baseline-discounted ICER of -£2079/QALY. Population-based screening 
lowered ovarian and breast cancer incidence by 0.34% and 0.62%. Assuming 71% testing uptake, this leads to 276 fewer ovarian and 508 fewer 
breast cancer cases. Overall, reduction in treatment costs led to a discounted cost savings of £3.7 million. Deterministic sensitivity analysis and 
94% of simulations on PSA (threshold £20 000) indicated that population screening is cost-effective, compared with current NHS policy.
Conclusion: Population-based screening for BRCA mutations is highly cost-effective compared with an FH-based approach in AJ women age 
30 years and older.
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Genetic testing for high-penetrance BRCA mutations is cur-
rently restricted to individuals from high-risk families fulfilling 
stringent family history (FH)–based criteria. However, a large 
proportion of BRCA carriers do not fulfil the current threshold 
for genetic testing. We found that more than 50% of BRCA car-
riers are missed by the FH-based approach, which is consistent 
with some earlier reports in which 40% to 63% (1–3) of carriers in 
population cohorts and 50% to 75% of carriers from cancer case 
series unselected for FH (4–9) lacked a strong FH of cancer. New 
gene-sequencing technologies (10) and the falling cost of genetic 
testing will make it feasible to test large populations in the near 
future. This could lead to new approaches capable of detecting a 
larger proportion of carriers of high-penetrance mutations and 
a change from the current FH-based approach. Systematic BRCA 
founder mutation (FM) testing in a low-risk Ashkenazi Jewish (AJ) 
population is acceptable and is not associated with differences in 
short-term psychological or quality-of-life outcomes compared 
with an FH-based approach (11). The AJ population could be the 
first population for whom population-based testing is feasible.
A health-economic evaluation is essential for an overall 
assessment of the balance of costs and health benefits in the 
context of setting public health policy for genetic testing of high-
penetrance cancer gene mutations. Decision analytical mode-
ling compares the expected costs and consequences of decision 
options by synthesizing information from multiple sources and 
applying mathematical techniques, usually with computer soft-
ware (12). The current clinical approach, which uses high-risk 
families for case identification, is more cost-effective than no 
genetic screening with a cost-effectiveness ratio (CER) of 4294 
euros per life-year-gained reported (13). In addition, preventive 
surgery is more cost-effective than screening in known BRCA 
and mismatch repair (MMR) gene carriers (14–16). However, 
health-economic data using truly population-based ascertain-
ment are limited. There is only one cost-utility analysis com-
paring population-based screening with no screening in the AJ 
population (17), which found that screening would prevent 2811 
ovarian cancers in the United States, for a (discounted) program 
cost of $8300 per quality-adjusted life-year (QALY). However, to 
date, the cost-effectiveness of a population-based approach has 
not been compared with an FH-based approach. Genetic Cancer 
Prediction through Population Screening (GCaPPS) is a rand-
omized trial (ISRCTN73338115) comparing outcomes of popu-
lation and FH-based approaches for genetic testing in UK AJ 
women. In order to provide policy makers with the best available 
evidence, we use data from the GCaPPS trial to describe a deci-
sion analysis model comparing both population and FH-based 
approaches for genetic-testing in AJ women.
Methods
A decision analytic model (Figure 1) was developed to compare the 
lifetime costs and effects of genetically screening all UK AJ women 
age 30 years and older for BRCA FM, compared with the current 
practice of screening using FH-based criteria (≥10% mutation risk) 
(Supplementary Table 1, available online). The model assumes that 
all women in the population screening arm and only those with a 
strong FH in the FH arm are offered genetic counseling and genetic 
testing. A 71% uptake rate of genetic testing (estimated from the 
GCaPPS study) was incorporated into the model. Genetic testing 
involved analysis for the three BRCA FM associated with Jewish 
descent in a National Health Service (NHS) genetics laboratory. In 
line with current guidelines (18,19) women testing positive were 
offered risk-reducing salpingo-oophorectomy (RRSO) to reduce 
their ovarian cancer risk (20,21) and MRI/mammography screening 
or risk-reducing mastectomy (RRM) (22) to reduce their breast can-
cer risk. Use of a selective estrogen receptor modulator (SERM) for 
breast cancer chemoprevention (23) was also included in the model 
as part of a sensitivity analysis, but ovarian cancer screening was 
excluded, as its clinical value remains uncertain (24). In line with 
guidelines on the reference case for economic evaluation from the 
National Institute of Health and Clinical Excellence (NICE), all costs 
and outcomes were discounted at 3.5% (25).
Probabilities
All pathway probabilities for the model are presented and 
explained in Table  1. A  one-way sensitivity analysis involved 
rerunning the model at both lower and upper values/limits of 
the 95% confidence interval or range of all probability param-
eters (Table 1) used in the model (Figures 2 and 3). Cancer inci-
dence was estimated by summing the probabilities of pathways 
ending in ovarian or breast cancer. The current estimated UK 
population of AJ women is 114 400 (26,27). The total population 
impact was estimated by multiplying the results per woman by 
81 224 (0.71*114 400). Additionally, the effect if all 114 400 women 
underwent testing was also calculated.
Costs
All costs are reported at 2010 prices and where required 
have been converted using the Hospital and Community 
Health Service Index (28). These are described in detail in 
Table 2.
Life-years
Life expectancy for women not developing cancer (age 53 years) 
was based on life-tables from the Office of National Statistics 
(29). The mean age for breast/ovarian cancer onset was age 
41.7/51.5  years for BRCA1 and 45.6/58.9  years for BRCA2 AJ 
women, respectively (30). To simplify the analysis, we used aver-
age ages for breast (43.5 years) and ovarian cancer (54.9 years) 
onset for BRCA1/BRCA2 carriers, obtained by assigning 
weights to the individual ages of onset for the relative popu-
lation prevalence of BRCA1 and BRCA2 FM ((1.32*AgeBRCA1)/2.45 
+ (1.13*AgeBRCA2)/2.45)). The mean ages for sporadic breast and 
ovarian cancer in AJ-women were 57 years and 63 years, respec-
tively (31–33). In the absence of AJ-specific survival data, five-
year survival rates were assumed to be the same as the general 
UK population (34). This model incorporates potential survival 
differences between BRCA1, BRCA2, and sporadic ovarian can-
cers (35,36). No statistically significant survival difference 
between BRCA and sporadic breast cancers has been reported 
(37,38). For ovarian cancer, the five-year survival for BRCA1 is 
44% (95% confidence interval [CI] = 40% to 48%) and for BRCA2 
52% (95% CI = 46% to 58%) (35), giving a composite five-year sur-
vival for BRCA1+BRCA2 (weighted by BRCA1 and BRCA2 preva-
lence) of 0.477 ((0.44*1.32/2.45)+(0.52*1.13/2.45)). After five years’ 
survival, the probability of death was assumed to be the same as 
the general population.
Quality-Adjusted Life-years (QALYs)
QALY is a measurement that expresses changes in length of 
life, while at the same time incorporating reductions in qual-
ity-of-life. Calculation of QALYs requires knowledge of quality-
of-life adjustment or utility weights for each health state in the 
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model. Utility weights are an indication of an individual’s pref-
erence for specific health states where 1 equals perfect health 
and 0 equals death. QALY equals survival in life-years multi-
plied by utility weight. No studies that measured utility scores 
directly for women undergoing RRSO were identified. A Dutch 
study found no measurable impact on generic quality-of-life in 
high-risk women undergoing RRSO (39). Therefore, we did not 
include a utility decrement for RRSO in our analysis. Havrilesky 
(40) reported detailed utility estimates related to various health 
states following ovarian cancer treatment using visual ana-
logue scale and time-trade-off (TTO) methods. As visual scales 
for comparing health state preferences are subject to inherent 
Figure 1. Decision model structure. The upper part of the model structure reflects a population-based approach to BRCA testing, and the lower part of the model 
depicts a family history (FH)–based approach. Each decision point in the model is called a “node,” and each path extending from a node is called a decision “branch.” 
Each branch represents a mutually exclusive course or outcome. Each decision is given a probability (probabilities p1 to p14 used in the model are explained in Table 1) 
highlighted in a white box along the decision branch. Values for each outcome are calculated. Cancer incidence was estimated by summing the probabilities of path-
ways ending in ovarian or breast cancer. Final outcomes (blue boxes on the right of the figure) of each path include development of breast cancer (BC), ovarian cancer 
(OC) and no breast/ovarian cancer (no OC or BC). BC = breast cancer; No OC or BC = no ovarian cancer or breast cancer developed; OC = ovarian cancer; RRSO = risk-
reducing salpingo-oophorectomy; RRM = risk-reducing mastectomy.
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biases and are generally less accurate (41), we utilized the TTO 
scores. We assumed 70% of women present with ovarian cancer 
at advanced stages (42,43), with a lower utility score for a new 
diagnosis at 0.55 (SD = 0.29), while the remainder presenting at 
early stages have a higher utility score of 0.81 (SD = 0.26). The 
end-stage-of-life utility score, where ovarian cancer patients 
did not survive the next year, was 0.16 (SD  =  0.25). Of those 
that survived initial chemotherapy, the chance of recurrence 
with early disease was 10.5% annually (44), and with advanced 
disease this would be 20.6% (42). For women with recurrent dis-
ease, the mean utility value was 0.5 (range = 0.4–0.61), and for 
women in remission the utility value was 0.83 (SD = 0.25) (40).
Of general population breast cancer, 10% is noninvasive/
DCIS, 90% is invasive, 95% of invasive cancer is early and locally 
advanced (41% = stage 1, 45% = stage 2, 9% = stage 3) (45–48), 
and 5% is advanced (stage 4) (45–47). In BRCA carriers, 20% of 
cancers were DCIS and 80% invasive (61%  =  stage 1)  (18,49). 
Utility weights for breast cancer were assumed as follows: 
advanced breast cancer was 0.65, early or locally advanced 
breast cancer was 0.71, remission was 0.81, recurrence was 
0.45; these were obtained from NICE guidelines (50,51). For 
those who survived initial chemotherapy, the chance of breast 
cancer recurrence/progression with early or locally advanced 
disease was 35% (47), and for recurrence with advanced dis-
ease it was 66% (52).
Statistical Analysis
For each branch of the decision model, the probability of being 
in each branch was calculated by multiplying together the path 
probabilities. The total costs and effects in terms of life-years 
and QALYs were then estimated by weighting the values for each 
Table 1. Probabilities of different pathways in the model*
Probability Value (95% CI) Description Source
P1 0.0245 (0.0131 to 0.0416) Population prevalence of BRCA FM GCaPPS
P2 0.52 (0.39 to 0.67) Probability that carrier will undergo RRM Evans (71)
P3 0.96 (0.8 to 0.96) Reduction in risk of ovarian cancer  
from RRSO
Finch (20), Rebbeck (21)
P4 0.2987 (0.2485 to 0.3539) Probability that carrier without RRSO will 
get ovarian cancer
Chen (61)
P5 0.0185 (0.0005 to 0.0989) Probability that a noncarrier will get  
ovarian cancer
CRUK (84)
P6 0.1238 (0.1043 to 0.1454) Probability of having a positive FH GCaPPS
P7 0.0938 (0.0637 to 0.1763) BRCA prevalence in FH positive individuals GCaPPS
P8 0.0203 (0.0114 to 0.0332) BRCA prevalence in FH negative individuals GCaPPS
P9 0.91 (0.62 to 0.98) Reduction in breast cancer risk from | 
RRM without RRSO
Rebbeck (22)
P10 0.53 (0.44 to 0.62) Probability that carrier without  
RRM will get breast cancer
Chen (61)
P11 0.13 (0.11 to 0.14) Probability that a noncarrier will  
get breast cancer with screening
CRUK (46), ONS (85)
P12 0.55 (0.30 to 0.75) Probability that carrier will follow-up  
with RRSO
Manchanda (62)
P13 0.49 (0.37 to 0.65) Reduction in risk of breast cancer  
from RRSO alone
Rebbeck (21)
P14 0.95 (0.78 to 0.99) Reduction in risk of breast cancer  
from RRM with RRSO
Rebbeck (22)
* CI = confidence interval; FH = family history; FM = founder mutations; GCaPPS = Genetic Cancer Prediction through Population Screening study; RRSO = risk-reduc-
ing salpingo-oophorectomy; RRM = risk-reducing mastectomy. P1: The probability of carrying a BRCA FM in the AJ population (p1 = 0.0245) is taken from the GCaPPS 
study, as it provides UK-based data and is consistent with reports from other countries (2,86). P2: The probability that BRCA1/2 carrier will undergo RRM is taken from 
an analysis of UK BRCA1/2 carriers by Evans et al. 2009. A composite uptake rate (p2 = 0.52) for BRCA1 (60% RRM rate) and BRCA2 (43% RRM rate) carriers weighted for 
the relative prevalence of BRCA1 and BRCA2 FM found in the London AJ population was computed (71). P3: The reduction in ovarian cancer risk obtained from RRSO 
(p3 = 0.96) is taken from previous studies, which report a 4% residual risk of primary peritoneal cancer following RRSO (20). P4: A wide range of ovarian cancer risks 
have been reported for BRCA carriers, with higher penetrance estimates found in carriers ascertained from high-risk families with multiple cancer cases (87). Our 
analysis uses ovarian cancer penetrance figures (40% for BRCA1, 18% for BRCA2) from a meta-analysis, corrected for ascertainment (61). To simplify the analysis, we 
have used a composite risk for BRCA1 and BRCA2 carriers (p4 = 0.2987), weighted for the relative prevalence of BRCA1 and BRCA2 FM found in the London AJ popula-
tion. The BRCA1 population prevalence is 0.0132, and BRCA2 population prevalence is 0.0113 (GCaPPS study). The overall risk of ovarian cancer in BRCA carriers is 
calculated as ((0.0132*0.4)/2.45 + (0.0113*0.18)/2.45). P5: The risk of ovarian cancer in a low-risk population (p5 = 0.0185) is obtained from Cancer Research UK (84). P6: 
The probability of having a strong FH of cancer fulfilling the current clinical criteria (FH-positive) is obtained from the population-based GCaPPS study (p6 = 0.1238 
or 128/1034). P7, P8: The BRCA prevalence in FH-positive (p7 = 0.09375) and FH-negative (p8 = 0.0203) individuals is also obtained from the GCaPPS study in which 
12/128 BRCA carriers detected were FH-positive and 15/740 were FH-negative. P9: Reduction in breast cancer risk from RRM in BRCA carriers not undergoing RRSO 
is taken from the PROSE study data by Rebbeck et al., JCO 2004 (22). P10: The breast cancer penetrance for BRCA carriers (57% for BRCA1 and 49% for BRCA2) is taken 
from a meta-analysis, corrected for ascertainment (61). To simplify the analysis, we have used a composite risk for BRCA1 and BRCA2 carriers (P10 = 0.53) weighted 
for the relative prevalence of BRCA1 and BRCA2 FM found in the London AJ population. The BRCA1 population prevalence is 0.0132, and BRCA2 population prevalence 
is 0.0113 (GCaPPS study). The overall risk of breast cancer in BRCA carriers is calculated as ((0.0132*0.57)/2.45 + (0.0113*0.49)/2.45). P11: The risk of breast cancer in a 
low-risk population is taken from Cancer Research UK and UK Office for National Statistics data (46,85). P12: Undergoing RRSO can be a complex decision-making 
process, and RRSO rates ranging from 0.3 to 0.75 have been reported in the literature (62,71,72,88). We have used the RRSO rate recently reported in high-risk women 
from London (p2 = 0.55), as it reflects the views of carriers from a London population and is within the range reported in the literature (62). P13: The reduction in 
breast cancer risk in premenopausal women undergoing RRSO is taken from a meta-analysis by Rebbeck et al. (21). P14: Reduction in breast cancer risk from RRM in 
BRCA carriers undergoing RRSO is taken from the PROSE study data by Rebbeck et al., JCO 2004 (22).
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branch by the probability of being in each branch. The incre-
mental cost-effectiveness ratio (ICER) was estimated by divid-
ing the difference in cost by the difference in effect. ICER = (Cost 
A–Cost B)/(Effect A–Effect B). By comparing this ICER with the 
cost-effectiveness threshold used by NICE (£20 000-£30 000/
QALY) (53), it was possible to determine whether or not pop-
ulation screening for all women was cost-effective compared 
with FH-based testing. To explore uncertainty in the results and 
robustness of the model, a one-way sensitivity analysis was 
undertaken by varying each parameter in the model and then 
rerunning the model to assess the impact on overall results. 
Probabilities and utility scores were varied according to their 
95% confidence intervals/range, where available, or by +/-10%, 
and costs were varied by +/-30%. In addition to the one-way 
sensitivity results, a probabilistic sensitivity analysis (PSA) 
was undertaken as recommended by NICE methods guidance 
(25,54). Any variation in model parameters/variables is likely 
to occur in parallel rather than independently of each other. 
In the PSA all variables are varied simultaneously across their 
distributions to further explore model uncertainty. We assigned 
costs a gamma distribution, probabilities a beta distribution, 
and utilities a log-normal distribution as suggested in the lit-
erature (55). The results of 1000 simulations were plotted on 
a cost-effectiveness acceptability curve showing the propor-
tion of simulations that indicated that the intervention was 
cost-effective at different willingness-to-pay thresholds. Other 
scenarios also explored included: 1) breast cancer prophylaxis 
with SERMs (tamoxifen/raloxifene) in BRCA carriers (19,23) and 
2) women opting for genetic testing at age 50 years (average age 
of menopause) with a median age for RRSO and RRM at 54 years 
(just below the weighted average age of ovarian cancer onset in 
BRCA1/BRCA2 carriers).
Results
The discounted and undiscounted lifetime costs, life-years, 
and QALYs for each branch in the decision model are given in 
Table  3. Overall, a population-screening approach saved more 
life-years (0.090) and QALYs (0.101) than an FH-based approach. 
This difference equated to 33 days’ gain in life expectancy for 
AJ women using a population-screening strategy compared with 
an FH-based one. Discounted results show a smaller overall gain 
in life-years and QALYs and overall cost difference, as discount-
ing adjusts costs and outcomes that occur in the future and the 
cost savings generated through prevention of future ovarian 
cancer cases is valued less. The baseline discounted ICER was 
-£2079 per QALY, indicating that population-based screening not 
only saves more QALYs but is also cost saving and is highly cost-
effective in AJ women. This is well below the NICE threshold of 
£20 000-£30 000/QALY. Population-based screening also lowered 
ovarian cancer incidence by 0.34% (from 2.49% to 2.15%) and low-
ered breast cancer incidence by 0.62% (from 13.31% to 12.69%). 
Assuming that 71% of the estimated 114 000 AJ women in the UK 
(26,27) undergo testing, the overall impact of a population-based 
strategy is a reduction in ovarian cancer and breast cancer by 
276 and 508 cases, respectively, at a discounted cost savings of 
Figure 2. Deterministic sensitivity analysis for model probabilities. One-way sensitivity analysis for all probabilities in terms of the incremental cost-effectiveness ratio 
(ICER) of population-based screening compared with a family history (FH)–based approach for BRCA testing. X-axis: ICER: cost (£) per quality-adjusted life-year (QALY) 
(discounted). Y-axis: probability parameters in the model. The model is run at both lower and upper values/limits of the 95% confidence interval or range of all prob-
ability parameters given in Table 1. “High value” represents outcomes for upper limit, and “Low value” represents outcomes for lower limit of the probability parameter. 
Outcomes to the left of the midline “0” value on the X-axis indicate that the model is cost saving. FH = family history; neg = negative; pos = positive; RRSO = risk-
reducing salpingo-oophorectomy; RRM = risk-reducing mastectomy.
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£3.7 million. Should the entire population undergo testing, the 
number of cancers potentially prevented would increase to 388 
for ovarian and 715 for breast cancers at a discounted cost sav-
ings of £5.2 million.
The results of the one-way sensitivity analysis (Figures 2,3) 
indicate that the upper/lower utility values, costs, penetrance 
estimates, and rate of uptake of preventive/risk-reducing sur-
gery have little influence on the overall results, and the model 
is cost saving at both upper and lower limits of these variables. 
However, the model is highly sensitive to the overall BRCA prev-
alence and BRCA prevalence in FH-negative women (Figure 2). 
At the lower limits of overall BRCA prevalence and BRCA preva-
lence in FH-positive individuals, the intervention was still just 
cost saving at -£183/QALY and -£631/QALY, respectively. At the 
lowest value for BRCA prevalence in FH-negative women, the 
ICER equals £3877 per QALY, well under the NICE threshold of 
£20 000 to £30 000 per QALY, indicating that population screening 
was still cost-effective, but no longer cost saving. At the highest 
BRCA prevalence rates in FH-positive and FH-negative women, 
the intervention was both more effective and cost saving.
The probabilistic sensitivity analysis results (Figure 4) shows 
that at a threshold of £20 000 94% of simulations indicate that 
population screening in AJ women is a cost-effective interven-
tion compared with current NHS policy. A scenario incorporat-
ing breast cancer prophylaxis with tamoxifen (premenopausal)/
raloxifene (postmenopausal) in BRCA carriers, as recently rec-
ommended by NICE (19), achieved a greater cost savings per 
QALY of -£2472 for population-based screening compared with 
FH-based testing. A further scenario where unaffected women 
age 50 years were screened for BRCA mutations (with a median 
age for RRSO and RRM = 54 years), also achieved a higher cost 
savings per QALY of -£2946.
Discussion
According to NICE, a cost-effectiveness analysis comparing 
the relative health outcomes and costs of interventions is the 
preferred form of economic evaluation, and QALY is the most 
suitable determinant of health benefit, reflecting both mortal-
ity and health-related quality-of-life effects (25). Value-based 
judgments are used to assign an appropriate price for health 
outcomes. This analysis focused on whether the cost differen-
tial between different interventions/strategies is worthwhile 
in terms of changes in health outcomes. Our decision analysis 
model addressed the topical issue of cost-effectiveness of a new 
population-based BRCA testing strategy in AJ women, made 
possible by identification of AJ founder mutations and advances 
in the efficiency/cost of technology for mutation detection. Our 
finding that a population screening program implemented in 
UK AJ women older than age 30 years will be cost saving com-
pared with the current FH-based one has important implica-
tions for clinical care, population/public health, and for health 
care providers and commissioners. There is potential within 
the UK for reduction of the number of ovarian cancers by 276 
Figure 3. Deterministic sensitivity analysis for model costs and utilities. One-way sensitivity analysis for all model costs and utility-score parameters in terms of the 
incremental cost-effectiveness ratio (ICER) of population-based screening compared with a family history (FH)–based approach for BRCA testing. X-axis: ICER: cost (£s) 
per quality-adjusted life-year (QALY) (discounted). Y-axis: cost and utility-score parameters in the model. The model is run at both lower and upper values/limits of 
the cost and utility-score parameters given in Table 2. “High value” represents outcomes for upper limit, and “Low value” represents outcomes for lower limit of these 
parameters. Outcomes to the left of the midline “0” value on the X-axis indicate that the model is cost saving. This analysis suggests that variation in costs and utility 
scores do not statistically significantly affect model outcomes. BC = breast cancer; FH = family history; neg = negative; OC = ovarian cancer; pos = positive; RRSO = risk-
reducing salpingo-oophorectomy; RRM = risk-reducing mastectomy.
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Table 2. Summary of costs used in model (2010 prices)*
Item Cost (£) Source
Cost of genetic testing 50 GCaPPS
Cost of counseling 33 GCaPPS, PSSRU unit costs of health and social care (89)
Cost of RRSO (and HRT) 2222 NHS reference costs (90), BNF (91)
Cost of ovarian cancer diagnosis and initial treatment 15,753 NHS reference costs (90), NICE guideline (92)
Yearly cost of ovarian cancer treatment and follow-up: 
years 1–2
612 NHS reference costs (90), NICE guideline (92)
Yearly cost of ovarian cancer  
treatment and follow-up: years 3–5
262 NHS reference costs (90), NICE guideline (92)
Terminal care cost with ovarian cancer 14,716 National Audit Office (93)
Cost of breast cancer screening general 330 Robertson 2011 (94), NHS reference cost (90)
Cost of breast cancer screening BRCA carriers 5983 NHS reference costs (90), NICE guideline famial breast cancer (19)
Cost of RRM 3222 NHS reference costs (90), weighted for 21% complication rate (18,95)
Cost of breast cancer treatment 15039 NHS reference costs (90), NICE guideline advanced breast cancer (50), 
NICE guidelines early and locally advanced breast cancer (96)
Yearly cost of breast cancer follow-up and adjuvant  
treatment if any (eg, Tamoxifen): years 1–5
1914 BNF (91), Robertson 2011 (94), NHS reference costs (90),
NICE guidelines early and locally advanced breast cancer (96)NICE 
guideline advanced breast cancer (50)National Costing Report. 
Implementing NICE guidance 2009 (47)
* All costs were varied by +/-30% in one-way sensitivity analysis. BNF = British National Formulary; GCaPPS = Genetic Cancer Prediction through Population Screen-
ing study; HRT = hormone replacement therapy; NHS = National Health Service; NICE = National Institutes for Health and Clinical Excellence; PSSRU = Personal Social 
Services Research Unit; RRSO = risk-reducing salpingo-oophorectomy, RRM = risk-reducing mastectomy. 
† Cost of genetic counseling/testing: based on pretest counseling time (45 minutes), 71% genetic testing uptake (GCaPPS study), and national unit cost assumed for genetic 
counselling = £44/h of client contact from PSSRU Unit costs of Health and Social Care 2010 (89,97). RRSO costs: based on national reference costs for an upper genital tract 
laparoscopic/endoscopic intermediate procedure (90). Costs of HRT (from BNF [91]) assume HRT is given from average age of RRSO to the average age of menopause 
(51 years). Ovarian cancer costs: Costs for ovarian cancer diagnosis and treatment were derived from national reference costs and a recent ovarian cancer guideline from 
NICE (90,92). We assumed cost of diagnosis includes a pelvic examination, ultrasound scan, CA125 test, CT scan, percutaneous biopsy, and peritoneal cytology. The cost of 
treatment included the reference cost for a lower and upper genital tract very complex major procedure and administration of chemotherapy based on six cycles of 
carboplatin and paclitaxel treatment. It was assumed that in years 1 and 2 treated survivors would have a further three consultant visits, a CT scan, and four CA125 tests 
each year. In years three to five years postsurgery, it was assumed that survivors would have two consultant visits and two CA125 tests. We were conservative in our cost 
estimates and did not include costs for additional investigations, treatment of recurrence, or management of complications in the analysis. Costs for terminal care for 
ovarian cancer were derived from end-of-life costs for cancer patients based on a report from the National Audit Office, UK (93). In line with NICE recommendations, 
future healthcare costs not associated with ovarian cancer were not considered (25). Breast Cancer Costs: Breast Cancer diagnosis and treatment costs were derived 
predominantly from: “National costing report- Implementing NICE guidance (Feb 2009),” which provides estimates of the national cost impact arising from implementa-
tion of NICE guidelines for diagnosis and treatment of early/locally advanced breast cancer and advanced breast cancer in England, UK (47); from UK Department of 
Health NHS reference costs 2010–2011 (90); the BNF (91) and other relevant NICE guidelines on breast cancer care in general and high risk populations (19,50,96). Cost of 
breast cancer screening: assumes for noncarriers routine mammography (eight mammograms between 50–70 years), as per UK NHS breast cancer screening program (98). 
Cost of breast screening for BRCA carriers is based on annual mammogram from age 40 to 69 years and annual MRI from age 30 to 49 years, as per NICE guidelines for 
familial breast cancer (19). Cost of RRM: obtained from NHS reference costs (90) weighted for a 21% complication rate (18,95). Cost of breast cancer treatment: In the 
general population, 10% of breast cancer is noninvasive DCIS; 90% breast cancer is invasive; 95% of invasive breast cancer is early and locally advanced (41% Stage 1, 45% 
stage 2, 9% stage 3 [45–48]); 5% of invasive breast cancer is advanced breast cancer (stage 4) (45–47); 35% of early and locally advanced breast cancer will progress to 
advanced breast cancer (NICE costing report, 2009) (47). In BRCA carriers, 20% of cancers are DCIS and 80% invasive (61% stage1) (18,49). The cost of diagnosis includes 
clinical examination, mammogram, ultrasound, and biopsy. Mean prevalence of Axillary lymph node metastasis in early invasive breast cancer is 31.4% (systematic 
reviews within the NICE breast cancer guideline [96] and breast cancer clinical outcome measures [BCCOM] project [99]). 30% node-positive rate is assumed for BRCA 
breast cancer (based on screening studies in familial breast cancer, breast cancer case series, and Early Breast Cancer Trialists’ Collaborative Group data) (49,100–103). Cost 
of sentinel lymph node biopsy (SLNB): from NICE national costing report (47). SLNB for staging axilla for early invasive breast cancer and no evidence of lymph node 
involvement on Ultrasound (US)/negative US–guided biopsy (73% of invasive cancers). Cost of axillary lymph node dissection (ALND): assumed to be 25% of cost of breast 
surgery, as per NICE guideline development group recommendation (47), undertaken for lymph node–positive cancers (31% early and locally advanced invasive cancers) 
(47,96). Breast surgery costs: This includes costs of breast conserving surgery (assumed for all noninvasive cancers, and 75% of early/locally advanced [stage 1–3] invasive 
cancers); and costs of mastectomy with reconstruction (for 25% early/locally advanced cancers). Costs are obtained from the national NHS reference costs (90). 
Radiotherapy and chemotherapy: Invasive breast cancers that are not low risk (99,104,105) receive adjuvant treatment in line with NICE guidelines. Costs include 
radiotherapy costs for 60% of early invasive/locally advanced, radiotherapy and chemotherapy costs for 40% early invasive/locally advanced, and chemotherapy costs for 
all advanced cancers. Radiotherapy costs include planning and 40Gy, 15 times over three weeks (NICE guidelines [96]) or palliative treatment, taken form national NHS 
reference costs (90). Chemotherapy costs (based on polychemotherapy) (100) include administration costs, costs of 1st and 2nd line therapy, and toxicity from NICE 
guidelines (47,50). All costs are adjusted for BRCA breast cancers for difference in stage at presentation and 20% cancers being noninvasive. 70% general population 
invasive breast cancers are ER-positive; 15% early invasive breast cancers and 25% advanced breast cancers are HER2-positive (50,96). 27% BRCA1 and 67% BRCA2 breast 
cancers are ER-positive; 5% BRCA1 and 14% BRCA2 breast cancers are HER2-positive (101–103,106–108). ER and HER2 testing costs are obtained from a local NHS trust and 
included for all breast cancers. Endocrine therapy costs: As per NICE guidelines (47,96), ER-positive invasive breast cancers receive Tamoxifen 20 mg/day (premenopausal)/ 
Anastrazole 1 mg/day (postmenopausal) for five years: costs from the BNF (91). Rates are adjusted for BRCA carriers, ER positivity, and menopause status. Biphosphonate 
costs: 74% patients with advanced breast cancer will develop bone metastases, and 65% patients with bone metastases are offered bisphosphonates (47,109,110). As per 
NICE guidelines, costs (from BNF [91]) assume that 50% patients receive oral clodronate and ibandronic acid, and 50% receive intravenous zoledronic acid or pamidronate 
(47). Cost of Trastuzumab: for HER2-positive patients, given at three-week intervals for one year or until disease recurrence as per NICE guidelines. Costs obtained from 
NICE costing report (47). 35% of early/locally advanced breast cancer progress to advanced breast cancer (NICE guidelines) (47). Recurrence rates for early/locally advanced 
breast cancer (from the US National Surgical Adjuvant Breast and Bowel Project [NSABP]): 15.9% for node-positive (111) and 11% for node-negative (112) breast cancer: 
composite recurrence rate = 12.6% (weighted for 31% node-positive and 69% node-negative disease). Recurrence rate for advanced/metastatic breast cancer is 66% (34% 
relapse free five-year survival) (52). Follow-up costs: includes annual mammograms and six monthly consultations. MRI scan for all stage 4 cancers. Costs include a 
progression rate of 35% from early and locally advanced to advanced disease (47), and 66% relapse rate for advanced disease (52). Costs for terminal care for breast cancer 
were derived from end-of-life costs for cancer patients based on a report from the National Audit Office, UK (93). In line with NICE recommendations, future healthcare 
costs not associated with breast cancer were not considered (25). Chemoprevention (sensitivity analysis): Tamoxifen/Raloxifene for five years (19,23), from BNF (91). 
†For more detailed explanation, see Supplementary Table 2 (available online).
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and breast cancers by 508, combined with overall cost sav-
ings of £3.7 million. Should the entire relevant UK population 
undergo testing, the number of cancers potentially prevented 
would increase to 388 for ovarian and 715 for breast cancer at a 
discounted cost savings of £5.2 million. This compares favora-
bly with a number of interventions routinely used in clinical 
practice, which, while saving lives, cost more. For instance, 
the ICER for breast screening in BRCA1/BRCA2 carriers age 35 
to 49 years recommended by NICE (56) is £11 700(MRI alone) or 
£15 300 (MRI+mammography) per case of cancer detected (57). 
The ICER for paclitaxel and cisplatin for primary treatment of 
ovarian cancer ranges between $6600 and $22 000 per life-year 
gained (58,59).
This is the first report comparing cost-effectiveness of pop-
ulation screening for founder mutations of BRCA1/2 with the 
current standard of care. Our analysis incorporates impact on 
both breast and ovarian cancer risk and fulfills various require-
ments suggested by NICE for health-economic decision-mak-
ing. The “time horizon” in our analysis is long enough to reflect 
important differences in costs and outcomes (25). We use cur-
rent best practice as a comparator, QALYs to measure health 
outcomes, a 3.5% discount rate on costs and health outcomes, 
and, as far as possible, directly obtained population-based 
data for parameters in the analysis (25). This is the first model 
to incorporate BRCA prevalence in FH-negative individuals, 
and probabilities used in the model are consistent with other 
Table 3. Model outcomes for costs, life-years, and quality-adjusted life-years (QALYs), undiscounted and discounted
Population screening
Undiscounted Discounted
Probability Cost, £ Life-years QALYs Cost, £ Life-years QALYs
A. PS, carrier, RRM, RRSO, no OC/BC 0.0068 5197 53.00 53.00 3819 23.40 23.40
B. PS, carrier, RRM, RRSO, OC 0.0001 30 343 38.20 37.22 13550 19.75 19.39
C. PS, carrier, RRM, RRSO, BC 0.0002 27 936 46.92 45.63 28013 21.48 20.74
D. PS, carrier, RRM, no RRSO, no OC/BC 0.0038 2976 53.00 53.00 2766 23.40 23.40
E. PS, carrier, RRM, no RRSO, OC 0.0017 28 121 38.20 37.22 12497 19.75 19.39
F. PS, carrier, RRM, no RRSO, BC 0.0003 25 715 46.92 45.63 26960 21.48 20.74
G. PS, carrier, no RRM, RRSO, no OC/BC 0.0047 8297 53.00 53.00 5025 23.40 23.40
H. PS, carrier, no RRM, RRSO, OC 0.0001 33 442 38.20 37.22 16256 19.75 19.39
I. PS, carrier, no RRM, RRSO, BC 0.0017 31 036 46.92 45.63 29219 21.48 20.74
J. PS, carrier, no RRM, no RRSO, no OC/BC 0.0009 6075 53.00 53.00 3972 23.40 23.40
K. PS, carrier, no RRM, no RRSO, OC 0.0016 31 221 38.20 37.22 13703 19.75 19.39
L. PS, carrier, no RRM, no RRSO, BC 0.0028 28 814 46.92 45.63 28166 21.48 20.74
M. PS, noncarrier, no OC/BC 0.8355 423 53.00 53.00 213 23.40 23.40
N. PS, noncarrier, OC 0.0181 25 568 38.63 37.83 9274 19.99 19.72
O. PS, noncarrier, BC 0.1219 24 616 49.16 47.87 8868 22.50 22.05
Family history screening 1.0000
P. FH pos, carrier, RRM, RRSO, no OC/BC 0.0032 5197 53.0000 53.0000 3819 23.3988 23.3988
Q. FH pos, carrier, RRM, RRSO, OC 0.00004 30 343 38.2031 37.2150 13550 19.7536 19.3902
R. FH pos, carrier, RRM, RRSO, BC 0.0001 27 936 46.9236 45.6273 28013 21.4791 20.7432
S. FH pos, carrier, RRM, no RRSO, no OC/BC 0.0018 2976 53.0000 53.0000 2766 23.3988 23.3988
T. FH pos, carrier, RRM, no RRSO, OC 0.0008 28 121 38.2031 37.2150 12497 19.7536 19.3902
U. FH pos, carrier, RRM, no RRSO, BC 0.0001 25 715 46.9236 45.6273 26960 21.4791 20.7432
V. FH pos, carrier, no RRM, RRSO, no OC/BC 0.0022 8297 53.0000 53.0000 5025 23.3988 23.3988
W. FH pos, carrier, no RRM, RRSO, OC 0.0000 33 442 38.2031 37.2150 14756 19.7536 19.3902
X. FH pos, carrier, no RRM, RRSO, BC 0.0008 31 036 46.9236 45.6273 29219 21.4791 20.7432
Y. FH pos, carrier, no RRM, no RRSO, no OC/BC 0.0004 6075 53.0000 53.0000 3972 23.3988 23.3988
Z. FH pos, carrier, no RRM, no RRSO, OC 0.0007 31 221 38.2031 37.2150 13703 19.7536 19.3902
AA. FH pos, carrier, no RRM, no RRSO, BC 0.0013 28 814 46.9236 45.6273 28166 21.4791 20.7432
AB. FH pos, noncarrier, no OC/BC 0.0961 423 53.0000 53.0000 213 23.3988 23.3988
AC. FH pos, noncarrier, OC 0.0021 25 568 38.6324 37.8321 9274 19.9915 19.7169
AD. FH pos, noncarrier, BC 0.0140 24 616 49.1623 47.8660 8868 22.4951 22.0482
AE. FH neg, carrier, no OC/BC 0.0030 330 53.0000 53.0000 120 23.3988 23.3988
AF. FH neg, carrier, OC 0.0053 25 475 38.2031 37.2150 9851 19.7536 19.3902
AG. FH neg, carrier, BC 0.0095 23 069 46.9236 45.6273 24314 21.4791 20.7432
AH. FH neg, noncarrier, no OC/BC 0.7352 330 53.0000 53.0000 120 23.3988 23.3988
AI. FH neg, noncarrier, OC 0.0159 25 475 38.6324 37.8321 9182 19.9915 19.7169
AJ. FH neg, noncarrier, BC 0.1073 24 524 49.1623 47.8660 8775 22.4951 22.0482
Average population screening 0.1484* 4156 52.1912 52.0088 1677 23.2049 23.1406
Average family history screening 0.1587* 4233 52.1016 51.9078 1741 23.1799 23.1096
Incremental (difference) -0.0096 -77 0.090 0.101 -64 0.025 0.031
Cost per quality-adjusted life-year -767 -2079
Total population screening effect 837† -4467529 5166 5827 -3718526 1442 1789
Jewish population screened 81 224
* Cancer incidence. BC = breast cancer; FH = family history; neg = negative; OC = ovarian cancer; pos = positive; PS = population screening; QALY = quality-adjusted 
life-year; RRSO = risk-reducing salpingo-oophorectomy, RRM = risk-reducing mastectomy.
† Reduction in total number of cancer cases.
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reports in the literature (2,60). A  comparison of population-
screening for BRCA carriers vs no screening reported an ICER 
of $8300 per QALY (17). This higher value compared with the 
cost savings in our study could be attributable to our lower 
costs of testing, higher health care costs in the United States 
compared with the UK, and the beneficial impact of breast 
cancer prevention found in our study but not evaluated by 
the earlier study (17). Another advantage of our model is that 
it also includes genetic counseling costs, which would be a 
key component of any population-based testing strategy. This 
approach facilitates reflection of the positive and negative 
consequences of genetic testing and permits participants to 
make informed decisions based on their own values and opin-
ions. In order to minimize overestimating benefits of popula-
tion-based screening, we have been conservative in our use 
of ovarian and breast cancer penetrance estimates (corrected 
for ascertainment) (61), as well as our costs for ovarian and 
breast cancer diagnosis and treatment, by including a minimal 
subset of baseline costs. We did not include all costs for addi-
tional investigations, treatment of recurrence, or management 
of complications.
The deterministic sensitivity analysis permitted scrutiny 
of model outcomes and identification of variables that exert 
the most influence (Figures 2 and 3). The 95% confidence lim-
its for probabilities explored in our sensitivity analysis were 
quite wide, adding to the strength of the results. The lack of 
statistically significant effect on outcome despite 30% varia-
tion in costs indicates that costs of counseling, treatment, and 
prevention are less important in influencing the overall results. 
BRCA prevalence rates (P1, P8) emerged as the key variables of 
influence, given the higher model sensitivity to uncertainties 
around these values (Figure 2). That the model remains largely 
cost saving despite probabilities varying widely is reassuring. 
Even at low prevalence rates in FH-positive or FH-negative indi-
viduals, population testing remained cost-effective compared 
with the NICE threshold of £20 000 to £30 000 per QALY (53). 
Though we used an RRSO risk-reduction estimate (0.96) based 
on the residual risk of PPC (20), a lower rate of 0.8 (21) assessed 
in the sensitivity analysis showed it was still cost saving. RRSO 
rates vary with time, menopausal status, age, and parity (62). 
It is encouraging that even at low (0.3) RRSO rates, the model 
remains cost saving (Figure 2). The PSA undertaken adds to the 
robustness of our results and has been recommended by deci-
sion-making bodies (25). It permits simultaneous variation in 
probabilities of all parameters to fully characterize uncertain-
ties in the model and its effect on overall results. That 94% of 
simulations on PSA were cost-effective reconfirms the health-
economic benefit of a population-based approach to genetic 
testing.
Our model is limited by a number of assumptions. It does 
not incorporate any potential reduction in QALY following RRSO. 
Although RRSO is associated with worse menopausal symptoms 
and sexual function compared with women undergoing screen-
ing, no difference in generic quality-of-life has been reported 
(39,63,64) RRSO has also been linked with a higher risk of car-
diovascular disease (65,66) and osteoporosis. We felt that these 
downsides in premenopausal women may be balanced by the 
decrease in vasomotor symptoms, cardiovascular sequelae, 
and improved sexual function and osteo-protection seen with 
hormone replacement therapy (HRT) (63,65,67–69), as well as 
the reduction in cancer worry, perceived risk, and high overall 
satisfaction observed following RRSO (39,63). RRSO also halves 
the risk of subsequent breast cancer in premenopausal women 
(21), and available evidence suggests that HRT does not alter the 
statistically significant benefit of reduction in breast cancer risk 
obtained from bilateral oophorectomy (70).
Of BRCA carriers, 21% to 67% undergo risk-reducing mastec-
tomy (71–73). Addition of risk-reducing mastectomy or screening 
to RRSO further increases life expectancy in BRCA carriers (74). 
Our model incorporates the impact of breast screening already 
prevalent in the UK and includes the benefits of reduction in 
breast cancer risk obtained from RRSO (21) and risk-reducing 
mastectomy (RRM) (22). Our analysis does not incorporate any 
potential reduction in QALY following RRM. Although a negative 
impact on sexual pleasure and body image has been reported, 
no difference over time in sexual habit, discomfort, or activity 
Figure 4. Cost-effectiveness acceptability curve. Probabilistic sensitivity analysis in which all model parameters/variables are varied simultaneously across their distri-
butions to further explore model uncertainty. X-axis: Incremental cost-effectiveness ratio in terms of cost (£s)/quality-adjusted life-year. Y-axis: proportion of simula-
tions. The results of 1000 simulations were plotted on a cost-effectiveness acceptability curve showing the proportion of simulations (Y-axis), which indicated that the 
intervention was cost-effective at different willingness-to-pay thresholds (X-axis). The solid red line marks the proportion of simulations found to be cost-effective at 
the £20 000 threshold used by NICE. 94% simulations are cost-effective in this analysis.
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was documented (75). Lack of adverse effects on anxiety, depres-
sion, and health-related quality-of-life over time has also been 
reported (18,75,76). Additionally, any negative effects of RRM 
could be balanced by findings of significant decreases in anxi-
ety scores, improved social activity (75), reports of a majority of 
women finding RRM results to be consistent with their expecta-
tions, and high satisfaction with overall cosmetic results (76–79).
Although it can be hypothesized that FH-positive women 
may be more likely to adapt to their increased risk while 
FH-negative women have less of an opportunity to consider/
adapt to these issues before being tested, we did not find FH to 
statistically significantly affect quality-of-life outcomes in our 
GCaPPS trial. Not all of those undergoing genetic counseling will 
opt for genetic testing, and a reduced genetic testing uptake rate 
is built into the model costs. A total of 1034 (71%) of 1450 peo-
ple who made a genetic counseling appointment in the GCaPPS 
study underwent BRCA testing. This equals 1034 (89%) of the 
1168 who attended pretest counseling. FH did not statistically 
significantly influence uptake of testing in our population-based 
trial; hence, uptake using either FH or population approaches in 
our decision model is assumed to be similar (71%). This estimate 
lies well within the range of genetic testing rates (varying from 
66%–90%) (80–83), reported by previous studies of varying ascer-
tainment and sizes.
The intermarriage rate in the Jewish community is likely to 
lead to a fall in BRCA founder mutation prevalence. Twenty-five 
percent of Jewish marriages in the UK and 44% in the United 
States are to non-Jews, although only 50% of the population is 
married. Hence, overall, the impact of this is unlikely to affect 
more than 25% of the population. Assuming a BRCA prevalence 
of 2.5% for 75%, and 1% for 25% of the population, the overall 
population BRCA prevalence will be about 2.1%. Even if BRCA 
prevalence were 1% for 50% of the population, the overall pop-
ulation prevalence would be about 1.75%. These extremes are 
well within the 95% confidence intervals accounted for in our 
sensitivity analysis, which shows the model to be cost-effective.
Implementation of any national screening program has many 
challenges and raises important issues of logistics and quality 
control. It also requires raising public (and health professional) 
awareness/education, community engagement, and informa-
tion dissemination via media campaigns, which have an added 
cost. In the UK, screening programs are centrally coordinated 
by the national screening committee with fail-safe procedures 
and involve close coordination with GP/primary care and public 
health physicians. In addition, there is need for clearly defined 
downstream secondary and tertiary care pathways, developed in 
close coordination with clinical genetics teams, breast surgeons, 
gynecologists, and others responsible for the management of 
women found to be at high risk. While these pathways exist for 
high-risk women, they would need to be expanded prior to pro-
gram implementation. It would not be sensible or feasible for all 
women to undergo pretest counseling in tertiary high-risk cancer 
genetics clinics within a hospital setting, so a community-based 
approach would need to be explored. We have demonstrated that 
successful recruitment to such a population-based program for 
pretest counseling and BRCA testing outside a hospital setting is 
possible using a community- or high street–based model. More 
efficient, acceptable, and cost-effective ways of delivering infor-
mation on genetic risk will be needed for any population-based 
testing program to become a reality, and this area should be the 
focus of further research.
Health-economic assessments are critical for determining 
the appropriateness of resource allocation for cost-intensive 
population-based interventions. Rising health care costs and 
the ever-increasing price of new ovarian/breast cancer treat-
ments and drug therapies in a challenging economic environ-
ment further magnify the importance of newer cost-effective 
preventive strategies. An important advantage of population 
screening is the ability to identify BRCA carriers without a strong 
FH of cancer undetectable by an FH-based approach. This trans-
lates to 2322 additional UK AJ women (population prevalence 
=2.03%, 95% CI = 1.14% to 3.32%) who may benefit from access to 
screening/preventive options. The lack of statistically significant 
difference in short-term outcomes of anxiety, depression, qual-
ity-of-life, health anxiety, and overall impact of genetic testing 
between FH and population-based approaches reconfirms that 
population-based genetic testing in the majority of Jewish peo-
ple does not harm quality-of-life or psychological well-being, or 
lead to excessive health concerns (11).
The high cost-effectiveness of population-based testing in 
AJ women demonstrated in this analysis combined with the 
above findings should justify a change in the current paradigm, 
which is limited to an FH-based approach to BRCA testing in 
the AJ population. We conclude that introduction of systematic 
population testing for AJ BRCA1/2 founder mutations could save 
both lives and financial resources. Finally, we emphasise that 
the results from our analysis are related to population-based 
BRCA testing in AJ women and cannot be directly extrapolated 
to non-AJ populations with lower prevalence rates for BRCA1/2 
mutations. Nevertheless, as the cost of testing falls and the 
acceptance/understanding of this type of health intervention 
evolves in our societies, it is likely to become an increasingly 
important area for research and evaluation.
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